Premium
Phenotypic variation and antifungal susceptibility patterns of Candida albicans strains isolated from neutropenic patients
Author(s) -
Kiraz N.,
Angˇ Ö.,
Akgün Y.,
Erturan Z.
Publication year - 2000
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1046/j.1439-0507.2000.00569.x
Subject(s) - fluconazole , candida albicans , flucytosine , corpus albicans , microbiology and biotechnology , amphotericin b , biology , phenotype , antifungal , genetics , gene
The aim of this study was to investigate the relationship between phenotypes of Candida albicans strains isolated from clinical specimens and the susceptibility of the strains to three antifungal agents, fluconazole, amphotericin B and flucytosine. Oropharyngeal, gastrointestinal and urogenital tract specimens were collected from 122 neutropenic patients who had received no previous prophylactic treatment. Each of 122 C. albicans strains recovered was found to express one of the six phenotypes: smooth, fuzzy, irregular, star, ring and stipple. The mean minimum inhibitory concentrations (MICs) of fluconazole was consistently higher for C. albicans strains expressing the stipple phenotype. The mean MICs for the six phenotypes of C. albicans strains ranged between 1.22 and 7.94 μg ml −1 for fluconazole, 0.99 and 2.55 μg ml −1 for amphotericin B and 1.23 and 1.83 μg ml −1 for flucytosine. The antifungal susceptibility of the stipple phenotype requires attention, especially in patients who are clinically unresponsive to fluconazole chemotherapy or in cases of life‐threatening C. albicans infections of immunocompromised hosts. Long‐term use of fluconazole may explain the outcome of the resistant stipple phenotype.